|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0152018,
umls-concept:C0205420,
umls-concept:C0282460,
umls-concept:C0449851,
umls-concept:C0600558,
umls-concept:C1274040,
umls-concept:C1511253,
umls-concept:C1511572,
umls-concept:C1514888,
umls-concept:C1522449
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-8-31
|
|
pubmed:abstractText |
To determine the toxicities of neoadjuvant chemoradiotherapy using a three-drug regimen (cisplatin, 5-fluorouracil, and paclitaxel) and a conventional radiotherapy (RT) schedule combined with a concurrent boost technique during chemotherapy cycles, and to determine the rate of tumor response, overall survival, and impact of pathologic tumor response on survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
111-22
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15337546-Adenocarcinoma,
pubmed-meshheading:15337546-Adult,
pubmed-meshheading:15337546-Aged,
pubmed-meshheading:15337546-Aged, 80 and over,
pubmed-meshheading:15337546-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15337546-Carcinoma, Squamous Cell,
pubmed-meshheading:15337546-Cisplatin,
pubmed-meshheading:15337546-Esophageal Neoplasms,
pubmed-meshheading:15337546-Feasibility Studies,
pubmed-meshheading:15337546-Female,
pubmed-meshheading:15337546-Fluorouracil,
pubmed-meshheading:15337546-Humans,
pubmed-meshheading:15337546-Male,
pubmed-meshheading:15337546-Middle Aged,
pubmed-meshheading:15337546-Neoadjuvant Therapy,
pubmed-meshheading:15337546-Paclitaxel,
pubmed-meshheading:15337546-Radiotherapy,
pubmed-meshheading:15337546-Radiotherapy Dosage,
pubmed-meshheading:15337546-Survival Rate
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA. nchoi@partners.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
